CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL当代治疗研究：临床与实验
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL(英文缩写 CURR THER RES CLIN E),ISSN 0011-393X,eISSN 1879-0313,中文译名:当代治疗研究：临床与实验 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 未收录 | N/A |
| 2022 | 1.900 | N/A |
| 2023 | 1.600 | Q3 |
| 2024 | 1.500 | Q3 |
| 2025 | 3.000 | Q3 |
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL 最新收录文献
-
1. Prevalence and correlates of antinuclear antibodies in a Japanese community sample: a cross-sectional study.
1. 日本社区样本中抗核抗体的患病率及相关因素：一项横断面研究PMID:日期:2026-09-16Antinuclear antibodies (ANA) are among the most commonly used tests in autoimmune disease but are frequently positive in healthy individuals, with uncertain significance. Reported prevalence ranges from under 6% to over 45% across populations, and its determinants in healthy individuals are poorly defined. We examined ANA prevalence and its demographic and lifestyle correlates in a community sample in Japan. Serum samples were obtained from 1,017 community residents in a single prefecture in Japan. Age and sex were recorded for all participants; smoking status and allergic history were available for a subset (n = 467). ANA were measured by indirect immunofluorescence on HEp-2 cells; a 1:40 titer defined positivity. Associations were assessed using chi-square tests, logistic regression with linear and quadratic age terms, and multivariable logistic regression adjusting sequentially for age, sex, smoking, and allergic history. Among 1,017 participants (542 women and 475 men), overall ANA positivity was 18.3% (186/1,017). Positivity was significantly higher in women than in men (21.8% vs. 14.3%) and showed a U-shaped age pattern in women. ANA positivity was not associated with allergic history. Exploratory subgroup analysis showed higher positivity in current or former smokers than never-smokers among men. After adjustment for age, female sex was independently associated with ANA positivity (OR 1.72, 95% CI 1.24-2.40). In the lifestyle subset, female sex was the only independently associated factor after adjustment for age, smoking status, and allergic history. These data provide a population-specific baseline for ANA positivity in a Japanese community sample and confirm that prevalence is higher in women and varies with age. Because ANA is frequently measured and may precede autoimmune disease, longitudinal studies are needed to clarify whether incidental positivity in healthy individuals carries prognostic significance.
-
2. Potential interactions between creatine supplementation and prescription drugs: a narrative review and evidence-mapping perspective.
2. 肌酸补充剂与处方药之间的潜在相互作用：叙述性综述与证据映射视角PMID:日期:2026-09-06Creatine is one of the most widely used dietary supplements worldwide and is increasingly consumed by non-athletic populations, including older adults and individuals with chronic metabolic, neurological, and musculoskeletal conditions. Given the high prevalence of prescription drug use in these populations, concomitant use of creatine and medications is common. Several biological pathways suggest potential creatine-drug interactions, particularly related to renal handling and biomarker interpretation; however, the clinical relevance of such interactions remains unclear. A PRISMA-aligned narrative and evidence-mapping review was conducted. PubMed (MEDLINE), Scopus, and the Cochrane Library (CENTRAL) were searched without date restrictions for human studies evaluating oral creatine supplementation in the context of concomitant prescription drug use, pharmacokinetics, or interaction-related safety outcomes. Title and abstract screening was performed using predefined eligibility criteria. In parallel, major drug-drug interaction databases (UpToDate, DDInter, Medscape, DrugBank, Drugs.com, the Merck Manual, and the FDA Drug Development and Drug Interactions resource) were queried to contextualize potential interaction signals. Database searches identified 270 records, of which 132 unique articles remained after deduplication; none met inclusion criteria for full-text evaluation as human studies directly assessing creatine-drug interactions. Across drug-drug interaction databases, no clinically established creatine-drug interactions of moderate or high severity were identified. Reported interaction signals were uniformly classified as minor or theoretical and were primarily attributed to renal excretion-based mechanisms, without evidence of confirmed adverse clinical outcomes. Despite widespread real-world co-use of creatine supplements and prescription medications, no controlled human studies have directly evaluated creatine-drug interactions. Available evidence from creatine-drug interaction resources suggests predominantly low-severity, theoretical interaction signals rather than clinically confirmed interaction risk. However, the absence of documented clinical evidence should not be interpreted as evidence that interactions cannot occur, particularly in high-risk populations. These findings highlight a substantial evidence gap and underscore the need for targeted human studies to inform clinical guidance.
-
3. Paclitaxel, carboplatin, and cetuximab induction chemotherapy for locally advanced head and neck squamous cell carcinoma: A retrospective evaluation of treatment outcomes and safety.
3. 紫杉醇、卡铂和西妥昔单抗诱导化疗治疗局部晚期头颈部鳞状细胞癌：治疗结果和安全性的回顾性评估PMID:日期:2026-09-04Definitive chemoradiotherapy (CRT) for locally advanced head and neck squamous cell carcinoma (HNSCC) has limitations in advanced disease. Paclitaxel, carboplatin, and cetuximab (PCE) offers a potentially safer induction chemotherapy alternative. This study evaluated the feasibility and outcomes of PCE induction followed by CRT compared with CRT alone among patients with Stage IV HNSCC who received definitive CRT. This retrospective study included 128 patients with Stage IV HNSCC without distant metastases treated at a single institution (PCE group, n = 52; CRT group, n = 76). Survival analyses were restricted to the 127 patients who initiated definitive CRT, with time measured from CRT initiation to reduce immortal time bias; CRT completion was analyzed as an outcome, not an eligibility criterion. An adjusted Cox model accounted for baseline imbalances in T classification and Stage. Median follow-up was 17.0 months (PCE) and 65.0 months (CRT). The PCE group had more advanced disease (T3-4: 90.4% vs. 65.8%; Stage IVB: 34.6% vs. 15.8%). PCE achieved an 82.7% response rate, CRT completion in 51 of 52 patients (98.1%), and significantly higher cisplatin ≥200 mg/m² achievement (86.5% vs. 59.2%, = 0.002). PFS was longer with PCE in both unadjusted (HR: 0.515, 95% CI:0.271-0.980, = 0.043) and adjusted analysis (adjusted HR: 0.477, 95% CI:0.247-0.924, = 0.028). OS did not differ significantly (adjusted HR: 0.553, = 0.147), and its interpretation is limited by the shorter follow-up in the PCE group. Exploratory inflammatory and nutritional markers showed no reliable prognostic association. PCE induction was feasible, with a high rate of CRT completion and acceptable tolerability. PFS was longer in the PCE group after limited adjustment, whereas OS did not differ significantly. Given the retrospective, nonrandomized design, residual confounding, and shorter follow-up in the PCE group, these findings are hypothesis-generating and require confirmation in larger, prospective studies.
-
4. Dna aneuploidy and urothelial carcinoma: A meta-analysis.
4. DNA非整倍体与尿路上皮癌：一项荟萃分析PMID:日期:2026-09-01Urothelial carcinoma (UC) is regarded as the third most common cancer in adults, with a high incidence and mortality rate, and lacks specific tumor markers. With the advancement of technology, DNA ploidy analysis technology has become more convenient and efficient. Through meta-analysis of the correlation between DNA aneuploidy rate and UC prognosis, a more efficient UC prognosis indicator was discovered. Through searching PubMed, Web of Science, Embase and Cochrane Library database, we were able to identify the studies evaluating the prognostic value of DNA aneuploidy in UC. In all, 15 citations were included in this meta-analysis. Pooled results showed that DNA aneuploidy was significantly corrected with poor OS (HR = 4.32, 95% CI = 2.39-7.81, < 0.001), poor DFS (HR = 1.84, 95% CI = 1.36-2.50, < 0.001) and poor PFS (HR = 1.97, 95% CI = 1.37-2.83, < 0.001) in UC patients. However, subgroup analysis revealed that DNA aneuploidy was associated with poor OS in Asian and American, but not in European. Correlation analysis of clinical pathological features suggested that DNA aneuploidy was related to the TNM stage, tumor grade, lymph node metastasis, tumor type and recurrence of UC. Our meta-analysis showed the clinical value of DNA aneuploidy and its prognostic value in UC.
-
5. Prostate cancer initially misdiagnosed as prostatic abscess in a 36-year-old kidney transplant recipient.
5. 一名36岁肾移植受者的前列腺癌最初被误诊为前列腺脓肿PMID:日期:2026-07-27[中文摘要] 肾移植受者（RTRs）因长期免疫抑制，恶性肿瘤风险增加2-4倍。我们报告一例诊断极具挑战性的病例：36岁男性，肾移植病史16年，因会阴部疼痛、发热及前列腺特异性抗原（PSA）升高就诊，初诊为前列腺脓肿。超声引导下穿刺抽吸获得血性而非脓性液体，遂立即行活检，结果显示为低分化、PSA阴性前列腺腺癌，伴BRCA2、ATM及TP53突变。患者接受3D腹腔镜根治性前列腺切除术，术中采用改良手术入路以避开移植肾。术后基因组学检测发现多个DNA损伤修复基因突变，由此引发治疗困境：在移植受者中使用PARP抑制剂存在与他克莫司的药物相互作用及潜在肾毒性风险。随访1年时，PSA检测不到，移植肾功能稳定。本病例提示：肾移植受者出现盆腔症状时，若疑似脓肿的穿刺抽吸物为血性，应立即行组织活检；即使PSA处于“灰区”，其升高趋势亦值得进一步检查。
[英文摘要] Renal transplant recipients (RTRs) have a 2-4 fold increased risk of malignancy due to long-term immunosuppression. We report a diagnostically challenging case of a 36-year-old man with a 16-year history of renal transplantation who presented with perineal pain, fever, and rising prostate-specific antigen (PSA), initially diagnosed as prostatic abscess. Ultrasound-guided aspiration yielded bloody rather than purulent fluid, prompting immediate biopsy that revealed poorly differentiated, PSA-negative prostate adenocarcinoma with BRCA2, ATM, and TP53 mutations. He underwent 3D laparoscopic radical prostatectomy with a modified surgical approach to avoid the transplant kidney. Postoperative genomics revealed multiple DNA damage repair gene mutations, raising therapeutic dilemmas regarding PARP inhibitor use in transplant recipients due to drug interactions with tacrolimus and potential nephrotoxicity. At 1-year follow-up, PSA was undetectable and graft function stable. This case highlights that in RTRs with pelvic symptoms, bloody aspirate from a presumed abscess should prompt immediate tissue biopsy, and rising PSA trajectory warrants investigation even in the "gray zone."
-
6. Treatment satisfaction and patient preference for efanesoctocog alfa over previous hemophilia A treatment: Results from the XTEND-1 phase 3 clinical trial.
6. 对艾法奈索托可α的治療滿意度和患者偏好優於先前的A型血友病治療：XTEND-1第3期臨床試驗結果PMID:日期:2026-07-08[中文摘要] 血友病A的治疗包括凝血因子Ⅷ（FVIII）替代疗法的预防性治疗。采用标准半衰期和延长半衰期疗法时，患者仍会发生出血，且需每周给药2~4次，影响治疗依从性。Efanesoctocog alfa是一种每周一次的FVIII替代疗法，已获批用于治疗和预防所有年龄段血友病A患者的出血。旨在分析关键III期XTEND-1研究（NCT04161495）中，成人及青少年重型血友病A患者对每周一次efanesoctocog alfa与入组前预防性治疗方案的治疗偏好及满意度。通过治疗偏好调查评估第52周时的治疗偏好，并通过9项药物治疗满意度问卷（TSQM-9，涵盖总体满意度、有效性和便利性领域）评估基线和至第52周时的患者满意度，作为探索性事后患者报告结局分析。同时探讨治疗满意度及偏好与出血和地区之间的关系。在完成偏好调查的130例患者中，90.0%偏好efanesoctocog alfa而非其既往预防性治疗方案。按地区分析观察到相似趋势。最常见的原因包括“治疗频率更低”、“出血及出血相关并发症减少”和“感觉受到更好的保护”。在完成第52周TSQM-9评估的115例患者中，所有三个领域较基线均有统计学显著改善。至研究结束时，所有TSQM-9条目中选择“最佳应答”的患者比例均有所增加。第52周治疗满意度的改善与生活质量改善或出血事件之间无强相关性。大多数患者偏好预防性efanesoctocog alfa而非既往预防性治疗方案，且第52周时患者满意度得到改善。
[英文摘要] Treatments for Hemophilia A include prophylaxis with factor VIII (FVIII) replacement therapy. With standard and extended half-life therapies, patients still experience bleeds, and administration 2-4 times a week is needed, which affects adherence. Efanesoctocog alfa is a once-weekly FVIII replacement therapy approved to treat and prevent bleeding in patients with hemophilia A for all age groups. To analyze patient treatment preferences and satisfaction comparing once-weekly efanesoctocog alfa with pre-study prophylaxis in adults and adolescents with severe hemophilia A in the pivotal Phase 3 XTEND-1 study (NCT04161495). Exploratory post-hoc patient-reported outcomes were assessed by treatment preference at Week 52 (via a treatment preference survey) and patient satisfaction at baseline and up to Week 52 (via the 9-item Treatment Satisfaction Questionnaire for Medication [TSQM-9], covering: global satisfaction, effectiveness and convenience domains). Relationships between treatment satisfaction and preference versus bleeding and region were also explored. Of 130 patients who completed the preference survey, 90.0% preferred efanesoctocog alfa versus their previous prophylaxis regimen. Similar trends were observed by region. The most common reasons were 'less frequent treatment', 'bleeds and bleed-related complications reduction', and 'feel better protected'. Of 115 patients who completed the TSQM-9 at Week 52, there was a statistically significant improvement from baseline in all three domains. By study end, an increase in the proportion of patients selecting the "best response" for all TSQM-9 items was observed. There were no strong correlations with treatment satisfaction improvements at Week 52 and improvement in quality of life or bleeding episodes. Prophylactic efanesoctocog alfa was preferred to prior prophylactic regimens by most patients and improved patient satisfaction at 52 weeks.
-
7. {"_":"The effect of ascorbic acid supplementation on plasma leptin and adiponectin levels: Systematic review of and studies.","i":["in vivo","in vitro"]}
7. {"_":"补充抗坏血酸对血浆瘦素和脂联素水平的影响：体内和体外研究的系统综述。","i":["体内","体外"]}PMID:日期:2026-07-04[中文摘要] 瘦素在调节能量平衡和脂质储备中发挥关键作用。瘦素具有广泛的调节作用。脂联素是一种由脂肪细胞释放的脂肪因子，被认为是维持血糖水平、脂质代谢和胰岛素敏感性平衡的重要因素。近期研究探讨了抗坏血酸（AA）在代谢综合征管理中的作用，或高剂量AA补充对血清AA、瘦素和皮质醇参数的影响。本系统综述旨在明确AA补充与血浆瘦素及脂联素水平之间的关联及其背景。研究在PubMed/Medline、SCOPUS和Web of Science数据库进行了全面的系统检索，检索截止日期为2026年5月14日。初步共检索到948项研究，其中PubMed 187项、Web of Science 204项、Scopus数据库557项。剔除重复文献后，对剩余435篇文章通过审阅标题和摘要进行筛选，排除411篇不相关文章。在剩余的24篇文章中，有9篇符合本研究的纳入/排除标准。这些研究的结果表明，AA补充对脂肪组织细胞分泌脂联素具有正向影响。此外，研究还揭示了AA浓度与瘦素分泌之间的反向关系，提示AA补充可能降低瘦素水平。然而，人体研究关于AA对瘦素水平的影响呈现相互矛盾的证据。本系统综述表明，AA与脂联素呈正相关关系，与瘦素呈反向关系。
[英文摘要] Leptin plays a key role in regulating energy balance and lipid reserves. Leptin has a broad spectrum of regulatory actions. Adiponectin, an adipokine released by adipocytes, is recognized as an important factor in maintaining balance of blood glucose levels, lipid metabolism and insulin sensitivity. Recent studies have investigated the role of Ascorbic acid (AA) in the management of metabolic syndrome or the effect of high dose AA supplementation on serum AA, leptin and cortisol parameters. The purpose of the current systematic review was to identify associations between AA supplementation and plasma leptin and adiponectin level and setting. Comprehensive systematic search was performed in the PubMed/Medline, SCOPUS, and Web of Science databases up to 14 May 2026. A total of 948 studies were initially searched, 187 from PubMed, 204 from the Web of Science, and 557 from Scopus databases. After excluding the duplicates, the remaining 435 articles were screened by reviewing the title and abstract, and 411 unrelated articles were excluded. Of the remaining 24 articles, 9 articles met our inclusion/exclusion. The results obtained from the studies show that AA supplementation positively influences the secretion of adiponectin hormone from adipose tissue cells. Moreover, studies reveal an inverse relationship between AA concentration and leptin secretion, suggesting that AA supplementation may reduce leptin levels. However, human studies present conflicting evidence regarding the effect of AA on leptin levels. This systematic review demonstrates a positive relationship between AA and adiponectin and inverse relationship with leptin.
-
8. U-Shaped Association Between Serum Vitamin B12 and All-Cause Mortality in Adults With Obesity in the United States: A Prospective Cohort Study.
8. 美国肥胖成年人血清维生素B12与全因死亡率的U型关联：一项前瞻性队列研究PMID:日期:2026-06-27Despite the health benefits of vitamin B12, the potential association between vitamin B12 and all-cause mortality in populations with obesity remains understudied. Objective: To dissect this intrinsic association in adults with obesity and identify potential threshold effects. Methods: Data from 1999 to 2006 and 2011 to 2014 were retrieved from the National Health and Nutrition Examination Survey database. Three models were developed by adjusting for demographic characteristics, clinical factors, and comorbidities, and the relationship between vitamin B12 and all-cause mortality was further analyzed using Cox proportional hazards modelling, restricted cubic spline, survival curve analysis, and threshold effect analysis. Among 8301 participants with 1347 all-cause mortality over median follow-up of 9.08 years, the lowest groups Q1, Q2 and the highest group Q5 showed significantly increased all-cause mortality risk, although the for trend was nonsignificant. The unweighted threshold effect analysis showed an inflection point of 354 pmol/L for serum vitamin B12 levels. Below this point, lower B12 levels were associated with lower all-cause mortality, whereas above the threshold, higher vitamin B12 levels were associated with high all-cause mortality. All-cause mortality in the population with obesity showed an approximately U-shaped association with serum vitamin B12 levels. Maintaining serum B12 levels within 300 to 500 pmol/L is associated with a lower mortality risk. Owing to its observational design, causality cannot be inferred. Dynamic monitoring of vitamin B12 levels may help identify individuals at increased risk; however, further studies are needed to establish causality.
-
9. Association Between Perioperative Daprodustat Use and Early Posttransplant Graft Function in Living Donor Kidney Transplantation: A Propensity Score-Matched Retrospective Study.
9. 围手术期使用达普司他与活体供肾移植术后早期移植物功能之间的关联：一项倾向性评分匹配的回顾性研究PMID:日期:2026-06-20Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors, such as daprodustat, have demonstrated nephroprotective effects in preclinical models. However, their potential benefits in living donor kidney transplantation (LDKT) remain unclear. This study aimed to evaluate the effects of daprodustat on early posttransplant graft functions in LDKT. This single-center study evaluated LDKT recipients transplanted between August 2019 and November 2023. Patients were divided into the daprodustat group, who received the drug from preoperative Day 1 to postoperative Day 7, and the control group, who did not receive HIF-PH inhibitors during this period. Propensity score matching yielded 32 patients per group. The daprodustat group exhibited better graft function, reflected by higher estimated glomerular filtration rates in the early posttransplant period (mean ± standard deviation: Week 1, 53.3 ± 16.1 vs control 41.9 ± 17.9 mL/min/1.73 m²; = 0.001; Week 2, 55.3 ± 17.6 vs 46.0 ± 15.1; = 0.008). The incidence of slow graft function was significantly lower in the daprodustat group (0.0% vs 12.5%, = 0.039). No delayed graft function or thrombotic events occurred, and rejection did not differ between groups. These findings raise the possibility that perioperative daprodustat use may be associated with improved early graft function in LDKT, warranting further investigation.
-
10. Association Between the Use of Gabapentinoids and Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis.
10. 加巴喷丁类药物的使用与慢性阻塞性肺疾病恶化之间的关联：系统评价和荟萃分析PMID:日期:2026-06-12Evidence on gabapentinoids and its respiratory safety among the patients with chronic obstructive pulmonary disease(COPD) or asthma are remains uncertain. To evaluate the risk of exacerbations with gabapentinoids. A thorough literature search up to January 2026 was done across different databases to find real-world studies examining gabapentinoid exposure and respiratory outcomes. The pooled hazard ratios (HRs), 95% confidence interval (CI) and incidence rate ratios (IRRs) were calculate using random-effects models. Subgroup and sensitivity analysis were also performed for included studies. Quality of studies was evaluated using the Newcastle-Ottawa Scale. Four cohort studies (seven reports) included to this analysis. Gabapentinoids use did not associated with exacerbations of COPD or asthma (HR = 1.12, 95% CI: 0.93-1.34; p = 0.23; I = 90.7%). Further, analysis was stratified by gabapentinoid class and clinical indications. Subgroup analyses showed increased exacerbation risk with gabapentin (HR = 1.27, 95% CI: 1.02-1.58) and pregabalin (HR=1.37, 95% CI: 1.12-1.67), whereas mirogabalin showed no significant association. Elevated risk was consistent across clinical indications (HR = 1.42, 95% CI: 1.35-1.48). Incidence rate analysis demonstrated higher exacerbation incidence among gabapentinoid users (IRR = 1.41, 95% CI: 1.10-1.81; p=0.006). Overall, there was no significant association with gabapentinoids. However, gabapentin and pregabalin were linked to increased risk of exacerbations. Therefore, future long-term studies are required to establish this association with underlying biological mechanisms. [PROSPERO ID: CRD420251248968].